You are here:Home
»
Molecular Biology
»
MB-Apoptosis
»
Acinus (AAE7, ACN1, AC NON-UTILIZING 1, ACYL-ACTIVATING ENZYME 7, AT3G16910.1, Apoptotic Chromatin condensation inducer in nucleus) (Control Peptide)
Acinus (AAE7, ACN1, AC NON-UTILIZING 1, ACYL-ACTIVATING ENZYME 7, AT3G16910.1, Apoptotic
Chromatin condensation inducer in nucleus) (Control Peptide)
Pricing
For pricing information, USA customers sign in. Outside USA? Please contact your distributor for pricing. Specifications
| Peptide (DDPVRTAQVPSPPRGK) corresponding to amino acids 994 to 1009 of human AcinusL, 267 to 282 of human AcinusS’, or 236 to 251 of human AcinusS, which are identical to those of mouse Acinus (2). The selected antigenic sequence is located near the N-terminus of active peptide p17. For use with cat. no. A0600-03. | | | Catalog # | A0600-03P | | Chromatin condensation and nuclear fragmentation (CCNF) is the hallmark of apoptosis. CCNF is triggered by the activation of members of caspase family, caspase activated DNase (CAD/DFF40), and several novel proteins including AIF and CIDE (1). A new inducer of chromatin condensation was recently identified and designated Acinus (for apoptotic chromatin condensation inducer in the nucleus). Acinus is cleaved by caspase-3 and an additional unknown protease generating a small active peptide p17, which causes chromatin condensation in vitro when it is added to purified nuclei. Acinus also induces apoptotic chromatin condensation in cells. Acinus is ubiquitously expressed. Three different spliced forms of Acinus have been identified in human and mouse and designated AcinusL, AcinusS and AcinusS’ (2). | | Applications | Suitable for use as control peptide = in ELISA and Western Blot. Other applications not tested. | | Positive Control | K562 cell lysate | | Storage and Stability | May be stored at 4°C for short-term only. For long-term storage and to avoid repeated freezing and thawing, aliquot and add glycerol (40-50%). Freeze at -20°C or colder. Aliquots are stable for at least 6 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer. | | Source | Synthetic peptide | | Purity | Purified 60-70% | | Concentration | 0.2mg/ml | | Form | Supplied as a lyophilized powder. | | | Important Note | This product is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
External Links
|
